An interventional study of low-dose atropine eye drops and orthokeratology in Myopia, sponsored by Evidence Based Cataract Study Group. Status unknown at 2 sites in China. Open to participants aged 8 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-28.
Sponsored by Evidence Based Cataract Study Group · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 222 studies in Myopia with a site in China — 80 open to participants now, 102 under way, 4 of them phase 3. Myopia · China.
Among the 222 studies in Myopia with a site in China, this one is the 105th largest by planned enrollment of the 155 interventional ones that give a count, is one of 26 that started in 2022, is one of 136 with no phase, and was the 80th registered.
1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →80 of the 222 studies in Myopia with a site in China are open now. Recruiting first, the newest first:
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 3–6
Beijing Tongren Hospital · Sites in China
Healthy volunteers
Zhongshan Ophthalmic Center, Sun Yat-sen University · Sites in China
Ages 6–18 · Healthy volunteers
CooperVision International Limited (CVIL) · Sites in China
Ages 8–10
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 6–11 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.
This study: 8 Years to 18 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
222 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 8 · Phase 4 7
First in 2005; this study’s year is marked. 26 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 79 across 929 interventional studies indexed under Myopia.
Median enrollment 150 across the 155 interventional studies, 1,000 across the 67 observational. Of the 77 that completed or were terminated, 5 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 222 have an industry lead sponsor. The 10 most frequent:
Evidence Based Cataract Study Group is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Evidence Based Cataract Study Group has 1 study filed under Myopia — fewer than ten, so there is no comparison to draw.
35 of the studies in Myopia with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06708156Phase 3Oupushifang Pharmaceutical Technology Co., Ltd.The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression | 2026-12-31 |
| NCT07585877Zhongda HospitalEffect of Branched-Chain Amino Acid Supplementation on Myopia Progression | 2026-12-30 |
| NCT07119723Tianjin Medical University Eye HospitalEnvironmental Factors and Myopia Prevalence Among Uyghur Students in Remote China | 2026-12-30 |
| NCT07008001SightGlass Vision, Inc.Assessment of DOT Spectacles in Chinese Children Extension | 2026-12-31 |
| NCT06667037Zhongshan Ophthalmic Center, Sun Yat-sen UniversityOrthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control | 2026-12-31 |
Add all 35 to your calendar (.ics) → With an account.
Among the 222 studies in Myopia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Both orthokeratology and atropine eye drops are effective methods for myopia control, but few studies have compared them all together simultaneously. Therefore, the primary aim of the present study was to compare the effect of orthokeratology versus low-dose (0.01% and 0.02%) atropine on the control of myopia progression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Best corrected visual acuity less then 0.00 log MAR (minimum angle of resolution) units Cycloplegic SER of - 1.0 D or less in both eyes. An inter-eye cycloplegic SER difference of 1.00 D or more.
Exclusion Criteria:
Children with cycloplegic cylinder refraction of more than + 1.00 D or less than - 1.00 D.
History of binocular vision problems, including strabismus. History of known ocular disorders, including media opacities, macular dysgenesis, optic nerve hypoplasia, perinatal brain injury, buphthalmos, and retinopathy of prematurity.
History of medication use that might have affected the refractive results. Systemic or developmental problems that might have hindered refractive development.
Device: orthokeratology
Drug: low-dose atropine eye drops
low-dose atropine eye drops
orthokeratology, ortho-K lenses
Progression of myopia
The change of myopia (Ds)
Time frame: 1 year
Progression of axial length
The change of axial length (mm)
Time frame: 1 year
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Aug 2022; primary completion for Aug 2023, 12 months later.
Of 202 non-industry interventional studies with no phase under Myopia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 12 months is below that.
Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Evidence Based Cataract Study Group